Acute Hepatic Porphyria
7
1
2
3
Key Insights
Highlights
Success Rate
75% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 62/100
14.3%
1 terminated out of 7 trials
75.0%
-11.5% vs benchmark
14%
1 trials in Phase 3/4
33%
1 of 3 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 3 completed trials
Clinical Trials (7)
ELEVATE, a Registry of Patients With Acute Hepatic Porphyria (AHP)
Prevalence of Acute Hepatic Porphyria
Evaluating the Prevalence of Acute Hepatic Porphyria in Postural Tachycardia Syndrome
Expanded Access Protocol of Givosiran for Patients With Acute Hepatic Porphyria
ENVISION: A Study to Evaluate the Efficacy and Safety of Givosiran (ALN-AS1) in Patients With Acute Hepatic Porphyrias (AHP)
EXPLORE: A Natural History Study of Acute Hepatic Porphyria (AHP)
INSIGHT-AHP: A Study to Characterize the Prevalence of Acute Hepatic Porphyria (AHP) in Patients With Clinical Presentation and History Consistent With AHP